Background: Mathematical studies exploring the impact of booster vaccine doses on the recent COVID-19 waves are scarce, leading to ambiguity regarding the significance of booster doses.
Methods: A mathematical model with seven compartments was used to determine the basic and effective reproduction numbers and the proportion of infected people during the fifth wave of COVID-19. Using the next-generation matrix, we computed the effective reproduction parameter, Rt.
Results: During the fifth COVID-19 wave, the basic reproductive number in Thailand was calculated to be R0= 1.018691. Analytical analysis of the model revealed both local and global stability of the disease-free equilibrium and the presence of an endemic equilibrium. A dose-dependent decrease in the percentage of infected individuals was observed in the vaccinated population. The simulation results matched the real-world data of the infected patients, establishing the suitability of the model. Furthermore, our analysis suggested that people who had received vaccinations had a better recovery rate and that the death rate was the lowest among those who received the booster dose. The booster dose reduced the effective reproduction number over time, suggesting a vaccine efficacy rate of 0.92.
Conclusion: Our study employed a rigorous analytical approach to accurately describe the dynamics of the COVID-19 fifth wave in Thailand. Our findings demonstrated that administering a booster dose can significantly increase the vaccine efficacy rate, resulting in a lower effective reproduction number and a reduction in the number of infected individuals. These results have important implications for public health policymaking, as they provide useful information for the more effective forecasting of the pandemic and improving the efficiency of public health interventions. Moreover, our study contributes to the ongoing discourse on the effectiveness of booster doses in mitigating the impact of the COVID-19 pandemic. Essentially, our study suggests that administering a booster dose can substantially reduce the spread of the virus, supporting the case for widespread booster dose campaigns.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058444 | PMC |
http://dx.doi.org/10.3390/vaccines11030589 | DOI Listing |
BMC Infect Dis
January 2025
Department of Infectious Diseases, School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran.
Background: Vaccination against SARS-CoV-2 has been crucial in impeding virus spread and preventing fatal complications. Despite growing evidence of vaccine efficacy, data on its impact on hospitalized patients remain limited. We aimed to estimate the risk of mortality, ICU admission, and hospitalization length among hospitalized COVID-19 patients based on vaccination status.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Anaesthesia, Alex Ekwueme Federal University Teaching Hospital Abakaliki (AEFUTHA), Abakaliki, Ebonyi State, Nigeria.
Optimal (timely or cumulative age-appropriate) routine childhood immunization coverage (the receipt of every recommended vaccine dose at the recommended age and time-interval between doses) will enhance optimal protection against vaccine-preventable infectious diseases (VPDs) which have been causing significant morbidity and mortality and recurring outbreaks among children younger than five years. This study evaluated optimal routine childhood immunization coverage, and the predictors, in Ebonyi state, Nigeria. This study was a baseline cross-sectional household survey within a cluster-randomised controlled trial and was conducted from July 2 to 16, 2022 among consenting mother-child pairs, in which the children were aged 5-23 months (subdivided into 5-11 and 12-23 months), in 16 randomly selected geographical clusters where the primary health care (PHC) facilities were providing maternal and child health care services including weekly routine childhood immunization.
View Article and Find Full Text PDFLancet Microbe
January 2025
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Background: Although existing COVID-19 vaccines are known to be highly effective against severe disease and death, data are needed to assess their ability to reduce SARS-CoV-2 infection. We aimed to estimate the efficacy of the NVX-CoV2373 protein subunit vaccine against SARS-CoV-2 infection, regardless of symptoms, among adolescents.
Methods: We performed an ancillary observational study (SNIFF) to the phase 3, observer-blinded, randomised, placebo-controlled PREVENT-19 trial that assessed vaccine efficacy against symptomatic COVID-19 in the USA.
Infect Dis Ther
January 2025
Vaccine Research and Development, Pfizer R&D UK Ltd, Marlow, UK.
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) in infants were evaluated.
Methods: In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series).
J Infect Public Health
January 2025
Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. Electronic address:
Background: Given the limited available data about to the number of vaccine doses administered over an extended time in Iran, the immune status of vaccinated individuals and any potential disparities in this regard among those who received different numbers of vaccine doses remain unknown. Therefore, this study aimed to assess humoral immunity of individuals who received different doses of the COVID-19 vaccines in Iran.
Methods: This study was conducted from February, 2022 to December 2023 including 605 vaccinated subjects.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!